It sets out to identify the 'ultimate acid suppressant' to overcome several limitations of PPIs (lansoprazole (LPZ)), and it succeeded in discovering TAK-438, vonoprazan fumarate, which has strong gastric acid suppressive effects and a long duration of action. TAK-438 showed several advantages ...
A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 2011;337:797-804.Hori Y, Matsukawa J, Takeuchi T, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium- ...
Tu1054 TAK-438 Versus Lansoprazole 15 mg for Secondary Prevention of Peptic Ulcers Associated With Non-Steroidal Anti-Inflammatory Drug (NSAID) Therapy: Results of a Phase 3 Trial[J] . Yuji Mizokami,Kiyoshi Ashida,Satoshi Soen,Takashi Kawai,Kazunori Oda,Kojiro Saito,Nobuo Funao,Akira Nishimura,...
Tu1054 TAK-438 Versus Lansoprazole 15 mg for Secondary Prevention of Peptic Ulcers Associated With Non-Steroidal Anti-Inflammatory Drug (NSAID) Therapy: Results of a Phase 3 Trial[J] . Yuji Mizokami,Kiyoshi Ashida,Satoshi Soen,Takashi Kawai,Kazunori Oda,Kojiro Saito,Nobuo Funao,Akira Nishimura,...
Discovery of Vonoprazan Fumarate (TAK‐438) as a Novel, Potent and Long‐Lasting Potassium‐Competitive Acid Blockerdoi:10.1002/9783527800315.ch10CYP2C19 metabolismlansoprazolepotassium‐competitive acid blockerproton pump inhibitorTAK‐438vonoprazan fumarate...
In the above article [Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, Hirase K, Kajino M, and Inatomi N (2010) J Pharmacol Exp Ther 335 :[231–238][1]], it has been noted that the IC50 value of lansoprazole against porcine H+,K+-ATPase at pH 6.5 in [...